Physician
Lea Regional Hospital LLC
Lea Regional Hospital LLC was paid $10.62M by Medicaid between Jan 2018 and Nov 2021, across 168 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoLEA REGIONAL HOSPITAL LLC
HOBBS, NM 88240
HOBBS, NM 88240
33aNPI1285688697assigned 05/20/2006
33bProvider typeCardiovascular Disease Physician
28Total paid$10.62M
24GClaims217,445
24DCodes billed168
24AFirst – last monthJan 2018 – Nov 2021
Compared with peers
Next to other Cardiovascular Disease Physician providers in New Mexico
Rank by total paid#1 of 16
Median peer was paid$77K
This provider vs. median138×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 83,888 | $3.92M | |
| 2019 | 48,264 | $2.35M | |
| 2020 | 40,677 | $2.12M | |
| 2021 | 44,616 | $2.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 15,449 | 14,787 | $1.99M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 10,475 | 9,821 | $1.83M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.1% | 2,522 | 2,324 | $542K |
| G0378 | Hospital observation service, per hour | 3.9% | 848 | 799 | $411K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 894 | 864 | $341K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 1,778 | 1,673 | $311K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.4% | 4,202 | 3,782 | $255K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 4,552 | 3,964 | $255K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.4% | 952 | 905 | $250K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 6,341 | 5,874 | $221K |
| 80053 | Comprehensive metabolic panel | 2.1% | 15,788 | 14,241 | $218K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.8% | 4,849 | 4,602 | $196K |
156 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 4,413 | $178K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.5% | 1,264 | $164K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 4,087 | $161K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 1,697 | $154K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 16,068 | $147K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 4,694 | $137K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 3,611 | $118K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 1,374 | $107K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,983 | $101K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,935 | $99K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,891 | $97K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,980 | $93K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,636 | $81K |
| 84484 | <1% | 3,420 | $80K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 280 | $80K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,065 | $78K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,353 | $75K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,149 | $63K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 360 | $61K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,112 | $59K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,362 | $58K |
| 84703 | <1% | 3,069 | $55K | |
| 83690 | <1% | 3,461 | $53K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,418 | $53K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 762 | $52K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,826 | $52K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,005 | $51K |
| 82150 | <1% | 2,292 | $47K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 254 | $43K |
| 83880 | <1% | 1,896 | $42K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,178 | $37K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,174 | $37K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 790 | $35K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,413 | $35K |
| 87807 | <1% | 666 | $34K | |
| 76801 | <1% | 332 | $32K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 473 | $31K |
| 81001 | <1% | 6,328 | $31K | |
| 83735 | <1% | 2,251 | $31K | |
| 73562 | <1% | 376 | $30K | |
| 84702 | <1% | 902 | $28K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 292 | $27K |
| 80061 | Lipid panel | <1% | 1,729 | $25K |
| 82553 | <1% | 1,754 | $24K | |
| 73610 | <1% | 275 | $24K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,028 | $23K |
| 82550 | <1% | 1,995 | $22K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,726 | $22K |
| 87186 | <1% | 1,401 | $22K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 237 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,641 | $19K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 819 | $18K |
| 73030 | <1% | 275 | $18K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,358 | $17K |
| 87040 | <1% | 609 | $17K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 52 | $16K |
| 80055 | <1% | 230 | $16K | |
| 73110 | <1% | 239 | $14K | |
| 72100 | <1% | 198 | $14K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 505 | $14K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 213 | $14K |
| 84100 | <1% | 1,578 | $13K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 882 | $13K |
| 85610 | <1% | 2,778 | $13K | |
| 85027 | <1% | 2,189 | $13K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 134 | $13K |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 840 | $13K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 944 | $12K |
| 87088 | <1% | 1,057 | $12K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 30 | $12K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 127 | $11K |
| 80074 | <1% | 172 | $11K | |
| 73130 | <1% | 156 | $9K | |
| 83605 | <1% | 534 | $9K | |
| 64493 | <1% | 32 | $9K | |
| 86003 | <1% | 35 | $9K | |
| 81003 | <1% | 2,264 | $9K | |
| 73630 | <1% | 151 | $8K | |
| 82077 | <1% | 295 | $8K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 266 | $8K |
| 80179 | <1% | 196 | $7K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 493 | $7K |
| 80143 | <1% | 193 | $7K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 342 | $7K |
| 85730 | <1% | 589 | $7K | |
| 82962 | <1% | 2,137 | $7K | |
| 96376 | <1% | 547 | $7K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 214 | $6K |
| 76642 | <1% | 55 | $5K | |
| 86140 | <1% | 487 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 303 | $5K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 327 | $5K |
| 29125 | <1% | 44 | $5K | |
| 51702 | <1% | 73 | $5K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 70 | $5K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $5K |
| 64483 | <1% | 14 | $4K | |
| 74018 | <1% | 78 | $4K | |
| 64494 | <1% | 32 | $4K | |
| 64495 | <1% | 32 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $4K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 216 | $4K |
| 87070 | <1% | 306 | $4K | |
| 81005 | <1% | 711 | $4K | |
| 76775 | <1% | 38 | $4K | |
| 84439 | <1% | 279 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 110 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 285 | $3K |
| 12001 | <1% | 39 | $3K | |
| 86901 | <1% | 380 | $3K | |
| 86900 | <1% | 379 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 160 | $3K |
| 85379 | <1% | 182 | $3K | |
| 85651 | <1% | 364 | $3K | |
| 70486 | <1% | 15 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 63 | $2K |
| 64484 | <1% | 13 | $2K | |
| 87045 | <1% | 151 | $2K | |
| 93971 | <1% | 28 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 179 | $2K |
| 87324 | <1% | 108 | $2K | |
| 87081 | <1% | 188 | $2K | |
| 73502 | <1% | 39 | $1K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 140 | $1K |
| 82248 | <1% | 166 | $1K | |
| 86803 | <1% | 67 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 14 | $1K |
| 94762 | <1% | 21 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 64 | $1K |
| 73560 | <1% | 26 | $1K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 40 | $1K |
| 74019 | <1% | 15 | $1K | |
| 76536 | <1% | 13 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 175 | $1K |
| 73090 | <1% | 16 | $968.38 | |
| 93226 | <1% | 14 | $960.74 | |
| 93225 | <1% | 14 | $940.65 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 27 | $932.92 |
| 86850 | <1% | 104 | $927.88 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 61 | $878.93 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 106 | $830.31 |
| 74022 | <1% | 16 | $790.31 | |
| 87425 | <1% | 52 | $700.11 | |
| 89055 | <1% | 106 | $573.27 | |
| 82803 | <1% | 26 | $556.66 | |
| 82247 | <1% | 76 | $555.61 | |
| 90715 | <1% | 56 | $481.40 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 29 | $387.06 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 50 | $372.77 |
| 82950 | <1% | 53 | $335.86 | |
| 94760 | <1% | 27 | $311.35 | |
| 83540 | <1% | 27 | $275.66 | |
| 86005 | <1% | 29 | $244.56 | |
| 36600 | <1% | 13 | $201.67 | |
| 80050 | General health panel | <1% | 12 | $177.86 |
| 86592 | <1% | 15 | $146.38 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR / DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.